+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 70Years
All Genders
ID07907211

Randomized Trial Comparing Aspirin and Rivaroxaban for Blood Clot Prevention in Newly Diagnosed Multiple Myeloma Patients Receiving Immunomodulatory Therapy

Led by Chen Lijuan · Updated on 2026-10-30

200

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating aspirin versus rivaroxaban to prevent blood clots in patients newly diagnosed with multiple myeloma who are receiving immunomodulatory drug-based therapy. This trial aims to find out if rivaroxaban lowers the chance of venous thromboembolism VTE compared to aspirin and to compare their safety profiles, especially regarding bleeding events. The study is an open-label, randomized trial conducted at a single center following international guidelines for good clinical practice. Participants will be randomly assigned to receive either aspirin 100 mg daily or rivaroxaban 10 mg daily, taken orally for at least 6 months during their immunomodulatory drug treatment. No other blood-thinning agents are allowed during this period. The study assesses the occurrence of VTE events as the primary outcome and also evaluates adverse events and bleeding episodes. Risk assessment scores IMPEDE VTE and SAVED will be used to predict VTE risk. Throughout the study, participants will be followed for 12 months with evaluations every 3 months or when clinically needed to detect VTE. Safety monitoring includes recording adverse and serious adverse events. Researchers will collect data to compare the treatments effectiveness and risks, aiming to improve future thromboprophylaxis strategies for this patient group.

CONDITIONS

Brief Title

Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma

Research Team

L

Lijuan Chen

Q

Qinglin Shi

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here